Moderna Inc. agreed to pay German biotechnology company Immatics NV as much as $1.8 billion in a broad-ranging, multiyear collaboration on developing cancer therapies using messenger RNA and other technologies.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
